Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ventricular hypertrophy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    107 result(s) found for: Ventricular hypertrophy. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2008-008479-32 Sponsor Protocol Number: SR001 Start Date*: 2009-06-09
    Sponsor Name:University of Dundee
    Full Title: Do xanthine oxidase inhibitors reduce left ventricular hypertrophy and endothelial dysfunction in normotensive patients with chronic stable angina?
    Medical condition: Left ventricular hypertrophy Normotensive Chronic stable angina
    Disease: Version SOC Term Classification Code Term Level
    9.1 10049773 Left ventricular hypertrophy LLT
    9.1 10049194 Stable angina pectoris LLT
    9.1 10005754 Blood pressure normal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-008485-12 Sponsor Protocol Number: eb/lm/let390/ln950/20038 Start Date*: 2009-07-01
    Sponsor Name:University of Dundee
    Full Title: Do Xanthine Oxidase Inhibitors Regress Left ventricular Hypertrophy in Diabetes?
    Medical condition: Diabetes Left Ventricular Hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012602 Diabetes mellitus (incl subtypes) HLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002198-37 Sponsor Protocol Number: ENHVIE Start Date*: 2016-09-19
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE - IDIBELL
    Full Title: A single-center, randomized, open-label, 12 months study, with two parallel group to compare the efficacy of everolimus combination + tacrolimus in regression of left ventricular hypertrophy vs tac...
    Medical condition: Left ventricular hypertrophy in renal transplant patients in the maintenance phase .
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10049773 Left ventricular hypertrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001977-17 Sponsor Protocol Number: CVAA489ADE02 Start Date*: 2006-10-17
    Sponsor Name:Novartis Pharma GmbH
    Full Title: An open-label, randomized, parallel group study comparing the efficacy and safety of Amlodipine in combination with Valsartan compared to Losartan in combination with Hydrochlorothiazide given for ...
    Medical condition: patients with mild-to-moderate hypertension and left ventricular hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    8.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002083-33 Sponsor Protocol Number: 2012CV15 Start Date*: 2014-07-22
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Does Allopurinol regress Left Ventricular Hypertrophy in Patients with Treated Essential Hypertension?
    Medical condition: Left ventricular hypertrophy in hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.0 10007541 - Cardiac disorders 10049773 Left ventricular hypertrophy PT
    17.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004760-49 Sponsor Protocol Number: MK001 Start Date*: 2008-01-02
    Sponsor Name:University of Dundee
    Full Title: Do Xanthine Oxidase Inhibitors reduce both Left Ventricular Hypertrophy and Vascular Dysfunction in Cardiovascular patients with Renal Dysfunction?
    Medical condition: Chronic Kidney Disease Stage 3 Left Ventricular Hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025164 LVH LLT
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-000077-39 Sponsor Protocol Number: RECOGITO_V1.0_2014 Start Date*: 2014-02-27
    Sponsor Name:Sapienza University of Rome
    Full Title: Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phospho...
    Medical condition: Diabetic Cardiomyopathy, Diabetes Mellitus Type 2, Left Ventricular Hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    16.1 10007541 - Cardiac disorders 10049773 Left ventricular hypertrophy PT
    16.1 10007541 - Cardiac disorders 10012647 Diabetic cardiomyopathy PT
    16.1 10027433 - Metabolism and nutrition disorders 10012601 Diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-003189-26 Sponsor Protocol Number: Version1.2 Start Date*: 2014-12-01
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Metformin and its Effects on Myocardial Dimension and Left ventricular hypertrophy in normotensive patients with Coronary Artery Disease.
    Medical condition: Cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10027433 - Metabolism and nutrition disorders 10022489 Insulin resistance PT
    17.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    17.0 100000004849 10025164 LVH LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004724-21 Sponsor Protocol Number: 3963 Start Date*: 2007-12-21
    Sponsor Name:Hôpitaux Universitaires de Strasbourg
    Full Title: INTERET DES STATINES DANS LE RETRECISSEMENT AORTIQUE CHIRURGICAL : DU PRECONDITIONNEMENT MYOCARDIAQUE A L’INVERSION DU REMODELAGE VENTRICULAIRE
    Medical condition: Valvulopathie aortique - hypertrophie ventriculaire gauche
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002911 Aortic valvular disorders HLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001689-34 Sponsor Protocol Number: M10-030 Start Date*: 2008-04-24
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The PRIMO Study: Paricalcitol Capsules benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 3B/4. Estudio Primo: Beneficios de Paricalcitol cápsulas sob...
    Medical condition: Stage 3B/4 chronic kidney disease (CKD) in subjects who have left ventricular hypertrophy (LVH). Insuficiencia renal crónica en estadío 3B/4 en sujetos con hipertrofia ventricular izquierda.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) GB (Completed) IT (Completed) DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-005092-33 Sponsor Protocol Number: M10-221 Start Date*: 2008-06-10
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: The PRIMO II Study: Paricalcitol Injection benefits in Renal failure Induced cardiac Morbidity in Subjects with Chronic Kidney Disease Stage 5
    Medical condition: Stage 5 Chronic Kidney Disease (CKD) in subjects receiving hemodialysis who have left ventricular hypertrophy (LVH).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    9.1 10049773 Left ventricular hypertrophy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (Prematurely Ended) CZ (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002305-38 Sponsor Protocol Number: 2013CV11 Start Date*: 2015-01-21
    Sponsor Name:University of Dundee/ NHS Tayside
    Full Title: Does allopurinol reduce right ventricular mass in lung disease associated pulmonary hypertension?
    Medical condition: right ventricular hypertrophy associated with COPD or Interstitial Lung Disease and pulmonary hypertension
    Disease: Version SOC Term Classification Code Term Level
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10022611 Interstitial lung disease PT
    17.1 10038738 - Respiratory, thoracic and mediastinal disorders 10037400 Pulmonary hypertension PT
    17.1 10007541 - Cardiac disorders 10050326 Right ventricular hypertrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002376-95 Sponsor Protocol Number: RRK3535 Start Date*: 2009-01-05
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: Myocardial protection with Perhexiline in Left Ventricular Hypertrophy
    Medical condition: Patients with left ventricular hypertrophy undergoing aortic valve surgery (with or without coronary artery surgery)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-000715-33 Sponsor Protocol Number: 2015DM07 Start Date*: 2016-12-19
    Sponsor Name:University of Dundee & NHS Tayside
    Full Title: Does Dapaglifozin Regress Left Ventricular Hypertrophy In Patients With Type 2 Diabetes?
    Medical condition: Type 2 diabetes and left ventricular hypertrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10061024 Cardiac disorder PT
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003025-10 Sponsor Protocol Number: VIVID Start Date*: 2011-11-08
    Sponsor Name:King's College London [...]
    1. King's College London
    2. Guy's and St Thomas NHS Foundation Trust
    Full Title: Effect of active vitamin-D treatment on left ventricular hypertrophy in patients with type-2 diabetes and stage-3 chronic kidney disease.
    Medical condition: Left ventricular hypertrophy, type 2 diabetes, chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    20.0 10007541 - Cardiac disorders 10047295 Ventricular hypertrophy PT
    20.0 100000004861 10012612 Diabetes mellitus non insulin-dep LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000222-35 Sponsor Protocol Number: 2017-000222-35 Start Date*: 2017-07-21
    Sponsor Name:Medical University of Vienna
    Full Title: Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients – a randomized controlled trial
    Medical condition: Secondary hyperparathyroidism in adult patients with chronic kidney disease on hemodialysis therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000856-34 Sponsor Protocol Number: CSPP100A2316 Start Date*: 2005-08-26
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A 36 week, randomized, double-blind, multi-center, parallel group study comparing the efficacy and safety of aliskiren in combination with losartan compared to losartan on the regression of left ve...
    Medical condition: left ventricular hypertrophy in overweight patients with essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FI (Completed) DE (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001436-22 Sponsor Protocol Number: 2012CV07 Start Date*: 2013-08-06
    Sponsor Name:University of Dundee/NHS Tayside
    Full Title: Does ALlopurinol regress lefT ventricular hypertrophy in End stage REnal Disease: The ALTERED study
    Medical condition: Renal failure and left ventricular hypertrophy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004054-24 Sponsor Protocol Number: PHRCN2017/CAPRI-MARIE/NK Start Date*: 2019-03-18
    Sponsor Name:Centre Hospitalier Régional Universitaire de Nancy
    Full Title: Assessment of the (18)F-florbetaben whole-body PET imaging diagnostic performance for the detection of cardiac and extracardiac sites of amyloid deposits in patients with amyloidosis
    Medical condition: cardiac amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007509 Cardiac amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002636-25 Sponsor Protocol Number: RG_13-013NS Start Date*: 2013-09-11
    Sponsor Name:University of Birmingham
    Full Title: A Randomised Multicentre Open Label Blinded End Point Trial to Compare the Effects of Spironolactone to Chlortalidone on Left Ventricular Mass and Arterial Stiffness in Stage 3 Chronic Kidney Disease
    Medical condition: The condition under investigation is the disease changes that occur in patients with mild kidney disease that cause them to have a high rate of diseases such as heart failure, rhythm disturbance an...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 18:24:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA